Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ARRAY BIO Form 4 March 24, 20	PHARMA INC										
FORM	Δ								PPROVAL		
		RITIES AND EXCHANGE COMMISS shington, D.C. 20549			COMMISSION	OMB Number:	3235-0287				
Check this box if no longer subject to Section 16. Section 16.				GES IN BENEFICIAL OWNERSHIP OF SECURITIES				Expires: January 3 200 Estimated average burden hours per			
Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed purs s Section 17(a) of the Public		ding Con	ipany	Act of	ge Act of 1934, f 1935 or Sectio 40	response n	0.5		
(Print or Type R	esponses)										
CARRUTHERS MICHAEL Symbols ARE			2. Issuer Name and Ticker or Trading Symbol ARRAY BIOPHARMA INC ARRY]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) 3200 WALN	(First) (M	(Mont	e of Earliest Ti h/Day/Year) 3/2010	ransaction			Director X Officer (give below)		o Owner er (specify		
			mendment, Da Month/Day/Year	nendment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
BOULDER,	CO 80301						Form filed by M Person				
(City)	(State) (Zip) T	able I - Non-I	Derivative	Securi	ties Acc	quired, Disposed of	f, or Beneficial	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Ye	Code ar) (Instr. 8)	on(A) or D (D)	ispose 4 and (A) or	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	03/23/2010		S <u>(1)</u>	1,661	D	\$ 2.46	76,559	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	7. Titl Amou Under Secur (Instr.	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: ARRAY BIOPHARMA INC - Form 4

Reporting Owners

Reporting Owner Name / Addre	ess	Relationships						
	Director	10% Owner	Officer	Other				
CARRUTHERS MICHAEL 3200 WALNUT STREET BOULDER, CO 80301	,		CFO					
Signatures								
R. Michael Carruthers	03/24/2010							
**Signature of	Date							

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Person